


## MAPK13-IN-1

Cat. No.:	HY-18850		
CAS No.:	229002-10-2		
Molecular Formula:	C <sub>20</sub> H <sub>23</sub> N <sub>5</sub> O <sub>2</sub>		
Molecular Weight:	365.43		
Target:	p38 MAPK; Autophagy		
Pathway:	MAPK/ERK Pathway; Autophagy		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 250 mg/mL (684.13 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.7365 mL	13.6825 mL	27.3650 mL
	5 mM	0.5473 mL	2.7365 mL	5.4730 mL
	10 mM	0.2737 mL	1.3683 mL	2.7365 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.08 mg/mL (5.69 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.08 mg/mL (5.69 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.08 mg/mL (5.69 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

MPAK13-IN-1 is a MAPK13 (p38δ) inhibitor, with an IC<sub>50</sub> of 620 nM.

#### IC<sub>50</sub> & Target

MAPK13 (p38δ)  
 620 nM (IC<sub>50</sub>)

#### In Vitro

MPAK13-IN-1 exhibits an IC<sub>50</sub> of 4.63 μM in vero E6 cells<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[2]</sup>

Cell Line:	Vero E6 cells <sup>[2]</sup> .
Concentration:	0-100 $\mu$ M.
Incubation Time:	
Result:	Exhibited an IC <sub>50</sub> of 4.63 $\mu$ M.

## CUSTOMER VALIDATION

- Cell. 2020 Aug 6;182(3):685-712.e19.
- Stem Cells. 2022 May 27;40(5):508-522.
- Stem Cells. 26 February 2022.
- J Biol Chem. 2023 Aug 18;105175.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Yurtsever Z, et al. First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes. *Biochim Biophys Acta*. 2016 Nov;1860(11 Pt A):2335-2344.

[2]. Mehdi Bouhaddou, et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. *Cell*. 2020 Aug 6;182(3):685-712.e19.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA